Tag Archives: Quizartinib

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair. A lawsuit is now claiming that […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push

Five-year-old biotech TP Therapeutics has raised an $80 million mezzanine financing round and promoted its chief medical officer, Athena Countouriotis, to CEO. The San Diego-based biotech, which is developing targeted cancer drugs for people whose tumors resist other precision therapies, announced the changes Friday. TP Therapeutics is developing a drug called repotrectinib that targets a […]

Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on TP Therapeutics Names New CEO, Gets $80M More for Cancer Drug Push

Daiichi Sankyo Offers $315M Up Front to Get Ambit and Leukemia Drug

Japan’s Daiichi Sankyo has agreed to acquire San Diego cancer drug developer Ambit Biosciences (NASDAQ: AMBI) for $315 million in cash, with additional milestone payments that could bring the total to $410 million. The transaction comes just over a year after another big Japanese drug maker, Astellas Pharma, officially ended its four-year partnership with Ambit […]

Posted in National blog main, San Diego, San Diego blog main | Tagged , , , , , , , , , , , , , | Comments Off on Daiichi Sankyo Offers $315M Up Front to Get Ambit and Leukemia Drug

San Diego Life Sciences Roundup: IPOs, ResMed, Ventrix, CovX, & More

Last week, there was only a trickle of life sciences news out of San Diego. This week the dam broke, and there’s a lot of news—including two IPO filings by San Diego biotechs. —San Diego’s Sophiris Bio, a startup developing a new drug treatment for benign prostate hyperplasia (BPH), or enlarged prostate, plans to raise […]

Posted in National top stories, San Diego, San Diego blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on San Diego Life Sciences Roundup: IPOs, ResMed, Ventrix, CovX, & More

San Diego’s Ambit Biosciences Raises $25M to Advance Leukemia Drug

Ambit Biosciences has gone through several course changes in the 12 years since it was founded. But Ambit CEO Michael Martino says the San Diego company would not be announcing $25 million raised from existing investors today unless Ambit was making significant progress on its current trajectory. “What the financing represents is a huge vote […]

Posted in National blog main, San Diego, San Diego blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on San Diego’s Ambit Biosciences Raises $25M to Advance Leukemia Drug

Ambit Biosciences Seeks $86M IPO as Market Warms Up

Ambit Biosciences, the San Diego-based biotech company in its third incarnation, is now gearing up to take the IPO leap. Ambit is hoping to raise as much as $86.3 million in an initial public offering underwritten by JP Morgan, Credit Suisse, Leerink Swann, and Wedbush PacGrow Life Sciences, according to an investor prospectus filed with […]

Posted in National blog main, San Diego, San Diego blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ambit Biosciences Seeks $86M IPO as Market Warms Up